Please login to the form below

Not currently logged in
Email:
Password:

inflammatory conditions

This page shows the latest inflammatory conditions news and features for those working in and with pharma, biotech and healthcare.

FDA approves new self-injection administration for Xolair

FDA approves new self-injection administration for Xolair

This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps. ... Today's approval reflects our commitment to continued innovation with

Latest news

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    However, we must not neglect the fact that, for non-COVID patients, many people have faced delays and cancellations for the treatment of debilitating conditions, such as Inflammatory Bowel Disease (IBD) ... With a focus on inflammatory and fibrotic

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    conditions. 2. AR101 – the first peanut allergy treatment. Potentially deadly allergies to food and other everyday substances are on the rise around the world – and there are currently very few therapies ... Boehringer Ingelheim) for psoriatic

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Celgene, will gain six months right of first refusal on Mesoblast's stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications, for global rights (excluding Japan),

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How a design mindset can lead to better medical outcomes
By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...

Infographics